Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2012. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically detailing changes in share interests arising from dividend reinvestment.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to a specific share transaction notification and does not contain financial statements or performance metrics.
Material Changes
The only material change reported is the increase in shareholdings for five individuals due to the reinvestment of dividends on February 6, 2012. The transaction price was 1423.208 pence per Ordinary share. The specific share increases were:
- Sir Andrew Witty: 26 shares
- Mr S M Bicknell: 70 shares
- Mr E J Gray: 7 shares
- Mr D S Redfern: 7 shares
- Mrs V A Whyte: 14 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly adheres to the requirements of Disclosure and Transparency Rule 3.1.4R(1)(a) regarding director share transactions.
Key Facts for Investor Verification
- Transaction Date: February 6, 2012.
- Transaction Type: Dividend reinvestment within an ISA.
- Share Price: 1423.208 pence per Ordinary share.
- Participants: Five senior executives, including CEO Sir Andrew Witty.
- Notification Date: February 7, 2012.